

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot # / Exp Date	NDC	UPC
MESALMINE DR TAB 1.2G TEV 120@	1373570A 06/30/2021; 1342499A 01/31/2021; 1354638A 03/31/2021; 1354639A 05/31/2021; 1358274A 05/31/2021; 1358448A 05/31/2021; 1364618A 05/31/2021; 1366195A 06/30/2021; 1342498A 12/31/2020; 1369885A 06/30/2021; 1403886A 06/30/2022; 1373571A 07/31/2021; 1388571A 01/31/2022; 1395725A 04/30/2022; 1396585A 04/30/2022; 1397550A 04/30/2022; 1399389A 04/30/2022; 1403885A 06/30/2022; 1369884A 05/31/2021	00591224522	30591224522

Teva is recalling the above item/lots due to out of specification dissolution results obtained during stability testing. This recall is to the retail level. Affected product started shipping April 11, 2019.